Chinese Journal of Pharmacovigilance ›› 2016, Vol. 13 ›› Issue (6): 378-379.
Previous Articles Next Articles
Received:2016-04-25
Revised:2016-07-22
Online:2016-06-20
Published:2016-07-22
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
| [1] Panichpisal K, Angulo-Pernett F, Selhi S, et al. Gitelman-like syndrome after cisplatin therapy: a case report and literature review[J]. BMC Nephrol, 2006, 7(1): 1-4. [2] Cheng C Y, Lin Y C, Chen J S, et al. Cisplatin-induced acute hyponatremia leading to a seizure and coma: a case report[J]. Chang Gung Med J, 2011, 34(6 Suppl): 48-51. [3] 何东宁, 王艳丽, 哈敏文. 国产紫杉醇致急性中枢神经系统毒性1例[J]. 中国新药杂志, 2012, 21(21): 2581-2582. [4] 赵晔. 紫杉醇致癫痫大发作1例[J]. 现代中西医结合杂志, 2003, 12(22): 2407-2407. [5] Lachkar S, Bota S, Nouvet G, et al. Acute encephalopathy after infusion of paclitaxel [J]. Revue des maladies respiratoires, 2006, 23(1 Pt 1): 73-77. [6] Ziske C G, Sch?ttker B, Gorschlüter M, et al. Acute transient encephalopathy after paclitaxel infusion: report of three cases.[J]. Annals of Oncology, 2002, 13(4):629-631. [7] Rook J, Rosser T, Fangusaro J, et al. Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma[J]. Pediatric blood & cancer, 2008, 50(3): 699-700. [8] O’Connor T L, Ellen K P D. Delayed Seizure Associated with Paclitaxel-Cremophor EL in a Patient with Early-Stage Breast Cancer[J]. Pharmacotherapy, 2009, 29(8):993-996. [9] Kandemir M, Kü?ükkaya B, Tepe M S, et al. Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy.[J]. Balkan Medical Journal, 2015, 32(4):421-425. [10] Rowinsky E K, Chaudhry V, Cornblath D R, et al. Neurotoxicity of Taxol.[J]. Jnci Monographs, 1993, (15):107-115. [11] Scripture C D, Figg W D, Sparreboom A. Paclitaxel chemotherapy: from empiricism to a mechanism-based formul ation strategy[J]. Ther Clin Risk Manag, 2005, 1(2): 107-114. |
| [1] | LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850. |
| [2] | WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855. |
| [3] | XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862. |
| [4] | CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875. |
| [5] | CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882. |
| [6] | ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888. |
| [7] | SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895. |
| [8] | SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919. |
| [9] | YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923. |
| [10] | KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927. |
| [11] | LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932. |
| [12] | LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936. |
| [13] | ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940. |
| [14] | ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943. |
| [15] | CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
